Anton Uvarov

Dr Uvarov has experience in the healthcare industry with a particular focus on neuroscience. Dr Uvarov has started his career in biotechnology investments as equities analyst with Citigroup. He is a co-founding director of several publicly listed companies in Australia including clinical stage companies such as Dimerix (ASX:DXB), Actinogen Medical (ASX:ACW) and Neuroscientific Biopharmaceuticals (ASX:NSB). He was previously on the board of Imugene (ASX:IMU), a late-stage clinical oncology company. Dr Uvarov is currently a Non-Executive Director at Neuroscientific Biopharmaceuticals (ASX:NSB), a clinical stage biotechnology company developing new treatments for neurodegenerative diseases and diseases caused by degeneration of the optic nerve. In the past three years Dr Uvarov also served as a Non-Executive Director at Nutritional Growth Solutions (ASX:NGS).